Krish Patel, MD
Specialities
- Lymphoma
- Chronic Lymphocytic Leukemia
- Immunotherapy
- Early-phase drug development
- Clinical Research
Education
Medical Degree: Duke University School of Medicine
Residency: Duke University Medical Center
Location
335 24th Avenue North, Suite 200
Nashville, Tennessee 37203
Phone: 615-329-7640
Fax: 615-234-7723
Language
English
Biography
Dr. Patel is a dual board-certified hematologist and medical oncologist at SCRI Oncology Partners and the director of lymphoma research at SCRI. Previously, he served as the Director of Hematologic Malignancies and Cell Therapy at the Swedish Cancer Institute in Seattle, Washington, where he led development of the program’s clinical standards for lymphoma care, assisted in the expansion of cell therapy services, and helped shape lymphoma research efforts. Dr. Patel was also a member of the Paul G. Allen Research Center at Seattle Cancer Institute, serving as a co-founding member of the Center for Immuno-oncology, where he collaborated on translational research related to immunotherapy in hematologic diseases.
Dr. Patel has been published in various medical journals, including New England Journal of Medicine, Blood, and Journal of Clinical Oncology. He is also a member of the ASCO Cancer Communications Committee, the CIBMTR Lymphoma Working Committee, and the National Planning Committee for the Lymphoma Research Foundation Lymphoma Rounds.
Philosophy
Dr. Patel recognizes each patient’s illness experience is unique and is focused on providing care that is both evidence-based and personalized to the individual patient. He values the importance of communication in the physician-patient experience and emphasizes shared decision making to help patients navigate their illness and find the support they need. As an experienced sub-specialist with expertise in lymphomas and cellular therapy, Dr. Patel’s goal is to align the individual needs and goals of each patient with the best tools available to achieve those goals. He is passionate about helping advance the standards of treatment through clinical trials that offer patients access to cutting edge therapies.
Relevant Research
Blood Advances
Consensus Recommendations from the 2024 Lymphoma Research Foundation Workshop on Treatment Selection and Sequencing in CLL or SLL
Blood
Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy
Journal of Clinical Oncology
Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma